PC 766B
Alternative Names: PC-766BLatest Information Update: 30 Aug 2007
At a glance
- Originator Sumitomo Pharmaceuticals
- Class Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jul 1998 No-Development-Reported for Cancer in Japan (Unknown route)
- 03 Nov 1994 Preclinical development for Cancer in Japan (Unknown route)